The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis
Open accessAbstract
BACKGROUND: In the elderly, traditional influenza inactivated vaccines are often only modestly immunogenic, owing to immunosenescence. Given that adjuvantation is a means of enhancing the immune response, the trivalent inactivated vaccine adjuvanted with MF59 (MF59-TIV) was specifically designed to overcome this problem. Considering that, for ethical reasons, the absolute effectiveness of an influenza vaccine in the elderly cannot be demonstrated in placebo-controlled studies, the present study aimed to assess the effectiveness of MF59-TIV in preventing influenza-related outcomes in the elderly. METHODS: We conducted a systematic review of observational studies aimed at evaluating the effectiveness of MF59-TIV against influenza-related outcomes. Results of single studies were pooled whenever possible. RESULTS: Of the 1993 papers screened, 11 (6 case-control, 3 cohort and 2 prospective case-control) studies were identified. Hospitalization due to pneumonia/influenza and laboratory-confirmed influenza were reported in more than one study, while other outcomes (influenza-like illness, cardio- and cerebrovascular accidents) were investigated only by one study each. Pooled analysis of four case-control studies showed an adjusted MF59-TIV effectiveness of 51% (95% CI: 39-61%) against hospitalizations for pneumonia/influenza among community-dwelling seniors. Pooled results of the adjusted vaccine effectiveness against laboratory-confirmed influenza were also high (60.1%), although the 95% CI passed through zero (-1.3 to 84.3%). Other single community-based studies showed very high effectiveness of MF59-TIV in preventing hospitalizations for acute coronary [87% (95% CI: 35-97%)] and cerebrovascular [93% (95% CI: 52-99%)] events. MF59-TIV proved highly effective [94% (95% CI: 47-100%] in reducing influenza-like illness among institutionalized elderly. Furthermore, MF59-TIV displayed greater efficacy than non-adjuvanted vaccines in preventing hospitalizations due to pneumonia/influenza [adjusted risk ratio 0.75 (95% CI: 0.57-0.98)] and laboratory-confirmed influenza [adjusted odds ratio 0.37 (0.14-0.96)]. CONCLUSIONS: Our results suggest that MF59-TIV is effective in reducing several influenza-related outcomes among the elderly, especially hospitalizations due to influenza-related complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In comparative vaccination trials of older individuals, MF59, widely used in Europe, outperformed the nonadjuvanted vaccine in inducing influenza virus-specific antibodies and improving clinical outcome”
From Successful and Maladaptive T Cell Aging (2017) · cites this paper as Domnich et al., 2017
In the citing paper
“emerging data following the recent development and deployment of new-generation, high-dose or adjuvanted influenza vaccines82 and an adjuvanted glycoprotein varicella zoster vaccine83 suggest that the provision of additional signals to the immune system by certain adjuvants (such as AS01 and MF59) can overcome immunosenescence.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
(2014) · Medical Entomology and Zoology · Cited by 17,633
Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments
Lo, C. K.-L., Mertz, D., & Loeb, M. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-45 · Cited by 2,477
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
Vaccines against influenza WHO position paper – November 2012.
(2012) · PubMed · Cited by 782
Vaccines for preventing influenza in the elderly
Demicheli, V., Jefferson, T., Pietrantonj, C. D., Ferroni, E., Thorning, S., Thomas, R. E., & Rivetti, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004876.pub4 · Cited by 712
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V (2005) · The Lancet · doi:10.1016/s0140-6736(05)67339-4 · Cited by 601
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy
Simonsen, L., Taylor, R. J., Viboud, C. G., Miller, M. A., & Jackson, L. A. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70236-0 · Cited by 520
Research works printed but not linked: 1
- Official Journal of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF>.
Cited by
Sorted by citations
Items 201–232 of 232
Impfungen bei Senioren: Ein Update
Kwetkat, A., Heppner, H. J., & Leischker, A. H. (2019) · Geriatrie-Report · doi:10.1007/s42090-019-0273-9
La gripe: 76 años de vacuna antigripal… ¡y de la hemaglutinina!
Navarro-Alonso, J.-A. (2020) · Revista Madrileña de Salud Pública · doi:10.36300/remasp.2020.056
Viruses, Vaccines and the Race for a Covid-19 Vaccine: A TutorialPreprint
Mani, S. (2020) · Preprints.org · doi:10.20944/preprints202009.0153.v1
Immunology and Nanotechnology: Effects and Affects
Banerjee, K., & Madhyastha, H. (2021) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-61021-0_2
The Same Combined Adjuvant NE+Rg1 Shows Different Immune Effects on Different Pathogen AntigensPreprint
Shan, P., Wang, Z., Li, J., Wei, D., Zhang, Z., Hao, S., Hou, Y., Wang, Y., Li, S., & Xu, J. (2021) · Research Square · doi:10.21203/rs.3.rs-361399/v1
Machado, A. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Li, Q., Liu, Z., Liu, Y., Chen, L., Shu, J., Jin, X., Li, C., & Kou, Z. (2021) · Vaccines · doi:10.3390/vaccines9121408
Pawelec, G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734836757.793573747
Hartman, L., Tiller, R., Wohl, D. A., & van Duin, D. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.024
Vaccine Basics and the Development and Rollout of COVID-19 Vaccines
Mani, S., & Griffin, D. O. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00018-x
MacIntyre, C. R., Yin, J. K., Felter, C., Menzies, R., Thommes, E. W., Largeron, N., Moa, A., Trent, M. J., Costantino, V., Choi, S., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100365
Bashir, S., Wilson, M., Ashiru-Oredope, D. A. I., & Murdan, S. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-35811-1_9
Impfen im Alter: eine Übersicht
Kwetkat, A., Leischker, A. H., Endres, A., & Heppner, H. J. (2023) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-023-02265-1
Tapia, B., Weitzel, C., Inzunza, J., Weitzel, J., & Muñoz-Mendoza, C. L. (2024) · Revista Chilena de Salud Pública · doi:10.5354/0719-5281.2023.74348
Aktuelle Impfempfehlungen für Erwachsene
Kwetkat, A., Leischker, A. H., Endres, A., & Heppner, H. J. (2024) · Pneumo News · doi:10.1007/s15033-024-4067-x
Influenza vaccine effectiveness in Iceland 2014–2022: A test-negative design
Thors, V. S., Vias, R. D., Björnsdóttir, K., Palsdottir, E. B., Guðfinnsdóttir, G. K., & Haraldsson, Á. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126981
Kwetkat, A., & Heppner, H. J. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21194-2.00025-4
Nguyen, T. H. O., Foo, I. J. H., Purcell, R. A., Tan, H., Deliyannis, G., Zhang, W., Carolan, L. A., Hadiprodjo, A. J., Huang, H. H., Allen, L. F., et al. (2025) · medRxiv · doi:10.1101/2025.07.22.25332020
Engineering mucosal immunity: Advanced vaccine platforms against respiratory pathogens
Wang, M., Chang, Q., Li, B., Yang, R., Chen, X., Bai, Y., He, H., & Zheng, B. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100040 · Cited by 3
Marcenac, P., Soto, G. M., Yau, T. S., Carreon, J. D., Romero, C., Gonzales, M., Rosa, S. L., Arriola, C. S., Prouty, M. G., Diaz, R. A. H., et al. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108205
Hydroxypropyl Cellulose Enhances Immune Responses to the Current Seasonal Influenza Vaccine in Mice
Kaewaroon, N., Yoshimoto, S., Muawan, L., Shichinohe, S., & Watanabe, T. (2025) · Microbiology and Immunology · doi:10.1111/1348-0421.70026
Jihyun, Y., Kim, J., Kwak, C., & Poo, H. R. (2022) · Figshare · doi:10.6084/m9.figshare.19845902
Influenza vaccine-specific CD4+ T cell responses are impaired in older adults
Saint-Charles, P., Hagen, M., Autaa, G., Bijvank, E., Beckers, L., van Beek, J., van Baarle, D., Weinberger, B., & Appay, V. (2026) · npj Vaccines · doi:10.1038/s41541-026-01437-5
Systematic Review of Safety of MF59-Adjuvanted Influenza Vaccine in Older Adults
Manzotti, M., Bengolea, A., & Vázquez, H. (2026) · Vaccines · doi:10.3390/vaccines14040360
CD25+ cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice
Zhang, Y. G., Liu, L., Chen, T., Li, M., Shi, X., & Liu, Y. (2026) · Virology · doi:10.1016/j.virol.2026.110938
Kim, E., Lee, M.-S., Khan, M. S., Huang, S., Lee, J., Jeong, D., & Gambotto, A. A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101236
Amicizia, D., Marchini, F., Schenone, I., Massaro, E., Landa, P., Nicosia, A., Orsi, A., Icardi, G., & Ansaldi, F. (2026) · Vaccines · doi:10.3390/vaccines14100883
Self-citationShim, E., Eun, B. W., & Choi, W. S. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1833971
Murdolo, L. D., Leong, S. L., Maddumage, J. C., D'Orsogna, L. J. A., Chatzileontiadou, D. S. M., Grant, E. J., & Gras, S. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70123
Analysis of cellular immune responses to Influenza vaccines
Ross, T. (2025) · ImmPort · doi:10.21430/m3mage1qcm
Testing vaccine efficacy using electrospray
Ainslie, K. M. (2024) · ImmPort · doi:10.21430/m3m2wehxf8
Kennedy, R. (2024) · ImmPort · doi:10.21430/m3iim8aers
Metadata
- Authors
- Domnich, A., Arata, L., Amicizia, D., Puig-Barberà, J., Gasparini, R., & Panatto, D.
- Affiliations
- University of Genoa (IT)
- Corresponding author
- Panatto, Donatella
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 35
- Issue
- 4
- Pages
- 513-520
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2566538631
- Cited by
- 229
- References
- 42
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 15 · 2023: 16 · 2022: 28 · 2021: 39 · 2020: 29 · 2019: 33 · 2018: 31 · 2017: 12
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Vaccine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- MF59, adjuvanted influenza vaccine, trivalent inactivated influenza vaccine, older adults, vaccine effectiveness, immunosenescence, laboratory-confirmed influenza, acute coronary events, cerebrovascular events, influenza-like illness, institutionalized elderly, community-dwelling older adults, influenza prevention
- MeSH terms
- Adjuvants, Immunologic, Aged, Aged, 80 and over, Humans, Influenza, Human, Influenza Vaccines, Polysorbates, Squalene, Vaccines, Inactivated, Treatment Outcome, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
